Abstract
Ravulizumab -(ULTOMIRIS (R)) is the first long-acting complement C5 inhibitor (administered intravenously every 8 weeks) to be approved in several cou......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
